FindTrial
Sign In

Target organ damage related gene evaluation using olmesartan in hypertensive patients with diabetes mellitus

Target organ damage related gene evaluation using olmesartan in hypertensive patients with diabetes mellitus - TOGETHER

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000700
Enrollment
200
Registered
2007-05-02
Start date
2007-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with diabetes mellitus

Interventions

administration of angiotensin receptor blockade (ARB:Olmesartan)

Sponsors

National Cardiovascular Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hypertension with diabetes mellitus, who has diabetic nephropathy not including severe renal failure patients with above serum creatinine 2.5mg. Hypertension with diabetes mellitus without renal failure

Exclusion criteria

Exclusion criteria: Severe hypertensive patients, who have BP above 180/110mmHg Female patients with pregnancy or possibility of pregnancy Patients just after acute myocardial infarction or stroke within a month Inappriate patients for this study

Design outcomes

Primary

MeasureTime frame
Gene polymorphisms related to to cardiovascular-renal protection by ARB in hypertensive patients with diabetes mellitus—

Secondary

MeasureTime frame
Gene polymorphisms related to to blood pressure reduction or glucose metabolism by ARB in hypertensive patients with diabetes mellitus—

Countries

Japan

Contacts

Public ContactKei Kamide

National Cardiovascular Center Division of Hypertension and Nephrology

kamide@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026